Entries |
Document | Title | Date |
20080199522 | TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION - The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1) drug and freely erodible filler are mixed with the core tablet, (2) the percentage erosion of the core tablet is approximately 40 to approximately 90%, and (3) the outer layer essentially does not contain the same drug as the above-mentioned drug. By releasing a drug after a specific lag time, it becomes possible to effectively deliver a drug to a specific site in the digestive tract. It is therefore useful as presented as a timed-release solid composition for oral administration of a drug that is to be effectively delivered in high concentrations to the afflicted site in the lower digestive tract, a drug that is to be effectively absorbed in the lower digestive tract, a drug that is effective for chronopharmacotherapy, etc. | 08-21-2008 |
20080206335 | MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FORMULATIONS - A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) formulation for oral administration comprises particles of said SSRI or a pharmaceutically acceptable salt thereof coated with rate-controlling polymer which allows controlled release of said SSRI, over a period of not less than about 12 hours following oral administration. The formulation, which contains for example fluvoxamine or a pharmaceutically acceptable salt thereof, is suitable for once or twice daily administration. The formulation can comprise a blend of two or more populations of particles, pellets or mini-tablets having different in vitro and/or in vivo release characteristics. | 08-28-2008 |
20080241241 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
20080248114 | ORAL OSMOTIC DRUG DELIVERY SYSTEM - The present invention relates, generally, to oral osmotic drug delivery systems, methods of preparing same, and methods of using oral osmotic drug delivery systems to provide controlled delivery of a drug. The oral osmotic drug delivery systems include a drug layer, an osmotic layer, and an outer coating surrounding the drug layer and osmotic layer, where the outer coating includes at least one opening therein that is provided adjacent the drug layer. The composition (% fines), shape, and weight gain of the oral osmotic delivery systems may be modified in order to provide for optimized release of the drug contained therein. | 10-09-2008 |
20080254121 | Multi-layer melatonin composition - A multi-layered solid dosage form for oral administration for a multi-phasic controlled release of Melatonin is described. The solid dosage form is useful as a composition to promote and maintain a state of sleep in an individual. | 10-16-2008 |
20080260825 | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 10-23-2008 |
20080268046 | Formulations with Controlled Release of Active Ingredient - The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable salts, hydrates, solvates and/or polymorphic forms thereof as active ingredient, and to the production thereof. The invention further relates to the use of these novel pharmaceutical dosage forms as medicaments, and to their use for producing medicaments for the treatment and/or prevention of disorders in humans and animals. | 10-30-2008 |
20080268047 | Controlled Release Multiple Layer Coatings - A process for making controlled release pharmaceutical formulations is provided, which comprises supplying a plurality of solutions with syringe pumps for fluid bed coating, coating a substrate with a pH dependent soluble polymer solution, coating the polymer coated substrate with at least one layer of a solution of a therapeutically active substance and at least one layer of a second polymer solution, and alternating the layers so that the number, order, and volume of the layers controls the release of the therapeutically active substance. In alternate embodiments, the consecutively applied layers may contain coating materials, active ingredients or a mixture of coating materials and active ingredients; the layers can be applied in varying order. Also provided is a system for applying the coatings, wherein the syringe pumps are controlled by a computer in accordance with predetermined instructions. | 10-30-2008 |
20080274181 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 11-06-2008 |
20080292702 | Solid Dispersion Comprising An Active Ingredient Having A Low Melting Point And Tablet For Oral Administration Comprising Same - A fused solid dispersion comprising an active ingredient having a melting point of 800 C or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 mVg can be conveniently compressed into a tablet without generating capping and sticking problems, and a tablet comprising said fused solid dispersion can maintain an uniform release rate over a prolonged time when orally administered. | 11-27-2008 |
20080311201 | MODIFIED RELEASE SOLID OR SEMI-SOLID DOSAGE FORMS - A solid or semi-solid pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods. | 12-18-2008 |
20090011018 | Sustained release formulation for tacrolimus - A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed. | 01-08-2009 |
20090011019 | PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY - A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract. | 01-08-2009 |
20090028942 | Sustained release compositions of alfuzosin - The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers. | 01-29-2009 |
20090035373 | PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND BLOOD PRESSURE REGULATION, KIT FOR CONTRACEPTION CONTAINING SAME AND METHOD OF PRODUCTION OF SAME - The pharmaceutical composition for contraception and regulating blood pressure includes daily dosage units, which contain 2.0 mg of dienogest and 0.030 mg of ethinyl estradiol, 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, or 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with at least one excipient and/or carrier. Each daily dosage unit may be a coated tablet for oral administration consisting of a tablet core and a coating around the core. The coating contains all of the ethinyl estradiol and a part of the dienogest, which are released in a non-retarded fashion. The tablet core contains another part of the dienogest that is released in a retarded fashion. The risk of folate deficiency-induced congenital malformations in the event of pregnancy may be reduced by including (6S)-5-methyltetrahydrofolate in each daily dosage unit. A kit for a 28-day cycle is also disclosed. | 02-05-2009 |
20090035374 | METHOD OF MAKING A SINGLE-STAGE PHARMACEUTICAL PREPARATION FOR ORAL THERAPY TO REGULATE BLOOD PRESSURE AND KIT CONTAINING SAME - The single-stage oral contraceptive preparation contains at least 21 daily dosage units, which each contain a contraceptive combination of 2.0 mg of dienogest (not an aidosterone antognist) and 0.030 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.015 mg of ethinyl estradiol, or of 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with one or more pharmaceutically acceptable excipients and/or carriers, and at the most 7 daily dosage units containing a placebo or no active ingredients. The contraceptive preparation also regulates the blood pressure, raising low blood pressure and lowering mildly elevated blood pressure, during its administration for contraception. It is especially suitable for long-duration use as a contraceptive preparation without risk of negatively influencing the blood pressure. | 02-05-2009 |
20090068264 | Clinical Applications of Tetrahydrobiopterin, Lipoic Acid and Their Salts and Methods of Preparing Tetrahydrobiopterin Bis-Lipoate - Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease, hearing loss and chronic glaucomas). A novel method for the preparation of TBL is also disclosed. | 03-12-2009 |
20090087488 | GALANTAMINE-CONTAINING CONTROLLED RELEASE ORAL DOSAGE FORMS, PROCESSES FOR THE PREPARATION THEREOF AND USE OF THE MANUFACTURE OF A MEDICAMENT - The present invention relates to controlled release oral dosage forms of galantamine or acceptable salts thereof and processes for the preparation thereof. | 04-02-2009 |
20090104264 | CONTROLLED RELEASE SOLID PREPARATION - The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing a combination of (1) an antacid, (2) an immediate-release part containing a compound unstable to acid and a basic substance, and (3) a sustained-release part containing a compound unstable to acid and a basic substance, and having a film that dissolves at pH 6.5 or above. | 04-23-2009 |
20090117184 | Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception - Gestagens, preferably dienogest, chlormadinone acetate or levonorgestrel, in combination with estrogens, for example ethinylestradiol, 17β-estradiol or estradiol valerate, and one or more pharmaceutically acceptable auxiliary agents/excipients provide lactose-free oral contraception. | 05-07-2009 |
20090123541 | Pharmaceutical Composition - The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
| 05-14-2009 |
20090130207 | Pharmaceutical Tablets Having a Relatively Inactive Segment - An immediate release drug containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug. | 05-21-2009 |
20090130208 | Modified release niacin formulations - Modified release niacin formulations, methods for making the formulations, and methods of using the formulations. | 05-21-2009 |
20090148525 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain potassium ATP (K | 06-11-2009 |
20090162434 | MESALAZINE TABLET - Disclosed are mesalazine tablets and a method for their preparation. The mesalazine tablets comprise a tablet core, a first coating layer, and a second coating layer. The tablet core comprises mesalazine; the first coating layer comprises a cellulose derivative and/or povidone, and the second coating layer comprises methacrylic acid/methyl methacrylate copolymer and an anti-tack agent. The tablets show a high degree of uniformity and reproducibility and release mesalazine starting at pH 6.8 and are used in the treatment of colorectal diseases. | 06-25-2009 |
20090175938 | Controlled Release Flurbiprofen and Muscle Relaxant Combinations - This invention is a novel controlled release (CR) flurbiprofen and muscle relaxant combinations for oral administration with anti-inflammatory, analgesic, myorelaxant activity and methods of its manufacture. The pharmaceutical composition of the present invention is administered orally in tablet, multilayer tablet, multicoated tablet and capsule form. | 07-09-2009 |
20090175939 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 07-09-2009 |
20090186082 | METHOD OF MANUFACTURING MODIFIED RELEASE DOSAGE FORMS - In one embodiment, a dosage form comprises: (a) at least one active ingredient; (b) a molded core which is solid at room temperature; and (c) a shell which is in contact with at least a portion of the core, wherein the dosage form provides modified release of the active ingredient upon contacting of the dosage form with a liquid medium. In another embodiment of this invention, a dosage form comprises: (a) at least one active ingredient; (b) a molded core comprising a plurality of particles; and (c) a shell which is in contact with at least a portion of the core, wherein the dosage form provides modified release of the active ingredient upon contacting of the dosage form with a liquid medium. | 07-23-2009 |
20090208572 | ORAL CONTROLLED RELEASE TABLET - A method of reducing the risk of alcohol-induced dose-dumping of a therapeutically active ingredient comprising administering to human subjects who have ingested alcohol an oral controlled release tablet; said tablet comprising:
| 08-20-2009 |
20090258067 | MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE - The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine. | 10-15-2009 |
20090263481 | LEVETIRACETAM FORMULATIONS - Pharmaceutical formulations comprising levetiracetam and having an inner solid phase and outer continuous phase, wherein one or both of the phases comprise at least one hydrophobic material, lipophilic material, or combination thereof. | 10-22-2009 |
20090269402 | MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE - The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially, surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine. | 10-29-2009 |
20090280174 | Solid Pharmaceutical Preparation - It is intended to provide a long-acting solid pharmaceutical preparation which has an immediate release part and a sustained release part containing tramadol or a pharmaceutically acceptable salt thereof, is fast-acting and stably has an excellent release property showing little pH dependency in the initial elution. The invention relates to a long-acting solid pharmaceutical preparation characterized by having an immediate release part and a sustained release part, containing tramadol or a pharmaceutically acceptable salt thereof as an active ingredient in both parts and containing partially pregelatinized starch and an excipient as additives in the immediate release part. The preparation of the invention is a long-acting preparation in which an effective blood concentration is reached rapidly after taking it for rapid pain-relief and a drug action can be sustained for a long time thereafter and is practical as a preparation showing a stable, pH-independent and rapid initial elution behavior and, further, having a sufficient hardness enough to meet the need for avoidance of defacement, cracking, chipping, etc. during tablet coating. | 11-12-2009 |
20090280175 | Multilayer Proton Pump Inhibitor Tablets - Multilayer tablets of a proton pump inhibitor essentially bioequivalent in terms of plasma C | 11-12-2009 |
20090280176 | CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM - A controlled release formulation of alprazolam for once a day administration to a mammalian subject, which formulation releases alprazolam along a pre-determined release profile, is provided. | 11-12-2009 |
20090297600 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND AN ANGIOTENSIN ANTAGONIST - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described. | 12-03-2009 |
20090317464 | METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS - The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition. | 12-24-2009 |
20090317465 | COMPOSITION AND METHOD OF PREPARATION OF RELEASE SYSTEMS FOR CONSTANT (ZERO-ORDER) RELEASE OF ACTIVE AGENTS - The present invention includes methods and compositions for pharmaceutical compositions that exhibit substantially constant release profile. The composition includes at least two layers with different drug to polymer ratios. The layers can be arranged in any order to achieve desirable pharmaceutical effects. | 12-24-2009 |
20100003320 | HYDROPHILIC/LIPOPHILIC POLYMERIC MATRIX DOSAGE FORMULATION - An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet. | 01-07-2010 |
20100008987 | Modified Release Pharmaceutical Composition of Bupropion Hydrochloride - A delayed extended release pharmaceutical composition includes a compressed core containing an effective amount of bupropion or its pharmaceutically acceptable salt, a water-attractant polymer. The core is preferably devoid of a stabilizer. The core is surrounded by an extended release layer, which is free of plasticizer and pore-forming agent. The extended release layer is surrounded by a delayed release layer. Alternating coats of extended release layer and delayed release layer may follow. A preferred extended release layer includes ethylcellulose and hydroxypropyl cellulose or hydroxypropyl methylcellulose and a preferred delayed release layer includes methacrylic acid copolymer and hydroxypropyl methylcellulose phthalate, lactose and a combination of triethyl citrate and polyethylene glycol and talc. A method of preparing the delayed extended release bupropion hydrochloride containing pharmaceutical composition is also disclosed. | 01-14-2010 |
20100015223 | Crush-Resistant Tablets Intended to Prevent Accidental Misuse and Unlawful Diversion - Water-insoluble matrix tablets which are capable of prolonged release of active principles liable to be diverted for drug addiction purposes, the said active principles being dispersed within a tabletting matrix composed of at least one excipient selected from the group consisting of pH-independent, water-insoluble delay polymers, inorganic excipients and mixtures thereof, and exhibiting a crush resistance of at least 4 MPa. | 01-21-2010 |
20100015224 | PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY - The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention. | 01-21-2010 |
20100021542 | EXTENDED RELEASE ORAL DOSAGE COMPOSITION - A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed. | 01-28-2010 |
20100040681 | Oral Sustained-Release Triple Layer Tablet - The present invention relates to an oral sustained-release triple layer tablet, more particularly, a triple layer tablet consisting of an inner immediate-release layer containing a pharmaceutically active ingredient and two outer layers containing swellable polymers. Upon exposure to aqueous media, the two outer layers swell to form gelled layers surrounding the lateral side of the inner layer rapidly, thereby control effectively the release of the pharmaceutically active ingredient from the inner immediate-release layer. | 02-18-2010 |
20100086592 | MODIFIED DOSAGE FORMS OF TACROLIMUS - The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described. | 04-08-2010 |
20100092556 | ALFUZOSIN FORMULATIONS, METHODS OF MAKING, AND METHODS OF USE - Alfuzosin compositions comprising a tablet core of alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, based on the total weight of the tablet core; and an extended-release coating substantially surrounding the tablet core comprising a release-retarding coating material, wherein the compositions are bioequivalent to the reference dosage form of NDA #021287 (UROXATRAL) are disclosed. Methods of making and using the alfuzosin compositions are also disclosed. | 04-15-2010 |
20100098757 | PROCESS FOR PRODUCTION OF BUPRENORPHINE PHARMACEUTICAL PREPARATION TO BE APPLIED TO MOUTH MUCOSA - The objective of the present invention is to provide a process for producing a buprenorphine pharmaceutical preparation to be applied to mouth mucosa. The process according to the present invention for producing a buprenorphine pharmaceutical preparation to be applied to mouth mucosa includes steps of: preparing a granule for an immediate-release layer containing a buprenorphine hydrochloride crystal having 90% cumulative diameter of 200 μm or less; preparing a granule for a sustained-release layer containing a buprenorphine hydrochloride crystal having 90% cumulative diameter of 250 μm or less; and tabletting the granule for the immediate-release layer and the granule for the sustained-release layer into a two-layer tablet. | 04-22-2010 |
20100104639 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 04-29-2010 |
20100112053 | GASTRIC RETENTION-TYPE SUSTAINED-RELEASE LEVODOPA PREPARATION - The present invention is to provide a levodopa preparation which is able to persistently release levodopa in the stomach, has a sufficient gastric residence time, is in an easily ingestible size and is able to be easily manufactured industrially with an object of maintaining a sustained concentration of levodopa in blood. It is a gastric retentive preparation for levodopa, characterized in that, the preparation contains a gastric resident layer showing a sufficient retentive property due to a high mechanical strength in the stomach and showing a good disintegrating property in an intestinal tract in addition to a drug releasing layer containing levodopa. | 05-06-2010 |
20100112054 | TABLETS AND DISCS WITH COMPARTMENTS WITH TWO OR MORE DRUGS FOR RELEASE AT CERTAIN INTERVALS AND WITH SPECIFIC RATES - The present invention includes systems, compositions and methods of making a multilayer modular release system, wherein the layers form a stack of active agent release layers, wherein the stack comprises a body and first and second ends and an impermeable coating surrounding the body of the stack, wherein the active agent is only release from the first, second or both the first and second ends of the stack by diffusion. | 05-06-2010 |
20100143469 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 06-10-2010 |
20100143470 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDES AND ANGIOTENSIN-II-RECEPTOR BLOCKERS - Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously. | 06-10-2010 |
20100143471 | NOVEL REDUCED DOSE PHARMACEUTICAL COMPOSITIONS OF FEXOFENADINE AND PSEUDOEPHEDRINE - A novel reduced dose pharmaceutical composition comprising combination of fexofenadine or salts thereof; and pseudoephedrine or salts thereof in therapeutically effective amount, for the treatment of allergic rhinitis and associated symptoms in pediatric population. | 06-10-2010 |
20100151022 | Controlled-release compositions - A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow; and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is relatively fast. The first matrix can be a cross-linked high amylose starch and the second matrix can be a mixture of polyvinyl acetate and polyvinylpyrrolidone. | 06-17-2010 |
20100151023 | Time delayed release mechanism for energizing composition and method of use - The present invention is directed to a time-release energizing supplement of the present invention comprising energizing ingredients coated by an enteric coating. The energizing ingredients comprise guarana seed extract, eleuthero root extract, tyrosine, and high amounts of B-complex vitamins. The B-complex vitamins preferably comprise thiamin, riboflavin, niacin, vitamin B6, and vitamin B12. The enteric coating of the time-release energizing supplement controls the release of the energizing ingredients inside the user's body and energizes the user by enhancing physical and metal performance over an extended period of time. | 06-17-2010 |
20100159004 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 06-24-2010 |
20100172984 | TABLET DOSAGE FORM COMPRISING CETIRIZINE AND PSEUDOEPHEDRINE - The present invention relates to a tablet dosage form comprising an immediate release component comprising cetirizine and an extended release component comprising pseudoephedrine. | 07-08-2010 |
20100172985 | Tablet Containing Cetirizine, Pseudoephedrine, and Naproxen Containing a Barrier Layer - In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer. | 07-08-2010 |
20100178341 | BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR - The present invention relates to a bilayered tablet comprising: a slow release layer comprising niacin and release retarding agent; and an immediate release layer comprising HMG-CoA reductase inhibitor. | 07-15-2010 |
20100221335 | SUSTAINED-RELEASE PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a preparation which is a sustained-release preparation capable of providing a dissolution profile that permits once-daily administration even in the case of a highly water-soluble drug, and which can exhibit stable drug dissolution behavior and can be reduced in its size; and a method for producing the same. A preparation containing a highly water-soluble drug, a gel-forming polymer, and a low-melting lipophilic substance is usable as a sustained-release preparation that permits once-daily administration, and enables reduction in its size and simple production thereof, and thus, the objects have been achieved. | 09-02-2010 |
20100247647 | SUSTAINED RELEASE TABLETS WITH HYDROMORPHONE - The invention relates to a tablet having a tablet core comprising a plurality of active ingredient-containing pellets and one or more pharmaceutically tolerated excipients and at least one coating applied to the tablet core, the active ingredient-containing pellets containing hydromorphone or a salt or a solvate thereof as active ingredient and having the following structure:
| 09-30-2010 |
20100255095 | PHARMACEUTICAL COMPOSITIONS OF FENOFIBRATE - The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions. | 10-07-2010 |
20100260841 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions - A method of treating atherosclerosis, dyslipidemias and related conditions is disclosed wherein a therapeutic dose of nicotinic acid, approximately 1 gram, is administered to the patient once daily as a starting dose, and the dose is thereafter raised within a few days or weeks to 2 grams for the duration of therapy. The nicotinic acid may be administered in combination with a selective DP receptor antagonist. The selective DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur. | 10-14-2010 |
20100260842 | PSEUDOEPHEDRINE PHARMACEUTICAL FORMULATIONS - Controlled-release pharmaceutical formulations comprising pseudoephedrine or any of its pharmaceutically acceptable salts, processes for preparing the pharmaceutical formulations, and methods of using the formulations. | 10-14-2010 |
20100316712 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS - The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration. | 12-16-2010 |
20100330179 | Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer - The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer. | 12-30-2010 |
20110008431 | THERAPEUTIC TABLET FOR POSTHERPETIC NEURALGIA AND METHOD OF TREATING POSTHERPETIC NEURALGIA - The present invention provides a tablet for treating postherpetic neuralgia and a method of treating postherpetic neuralgia with the use of the tablet. The therapeutic tablet for postherpetic neuralgia according to the present invention is characterized in comprising buprenorphine hydrochloride, having a double layer structure consisting of a quick-release layer and a sustained-release layer, wherein the tablet is adhesive to the oral mucosa. | 01-13-2011 |
20110008432 | Method for Treating a Patient in Need of Aspirin Therapy - The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer. | 01-13-2011 |
20110052687 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF PALIPERIDONE - The present invention provides an extended release tablet of paliperidone, comprising a) a core containing paliperidone and at least one water soluble and/or gellable polymer, b) a coating comprising at least one water insoluble or permeable polymer, and a water soluble and/or gellable polymer and optionally an enteric polymer. | 03-03-2011 |
20110052688 | SOLID DISPERSION COMPOSITION - A solid dispersion extended release tablet composition is provided. The composition comprises fluvastatin sodium and a polymer, wherein molecules of the fluvastatin sodium are separate from one another and dispersed in the polymer, and wherein the composition displays two distinct peaks at about 3.5 and 20.4.degrees 2θ of X-ray diffraction. | 03-03-2011 |
20110052689 | SUSTAINED RELEASE OF GUAIFENESIN - The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1: 1) to about nine-to-one (9: 1), more preferably a range of about three-to-two (3:2) to about six-to-one (6: 1), and most preferably in a range of about two-to-one (2: 1) to about four-to-one (4: 1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. | 03-03-2011 |
20110064807 | EXTENDED RELEASE FORMULATION OF LEVETIRACETAM - An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system. | 03-17-2011 |
20110064808 | EXTENDED RELEASE FORMULATION OF LEVETIRACETAM - The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect. | 03-17-2011 |
20110097400 | MAGNESIUM SYSTEM AND USE THEREOF IN THE COSMETICS INDUSTRY - A magnesium-based system suitable for use in skincare comprises (a) a first magnesium source in the form of a progressive-release oral tablet exhibiting in vitro, after 2 h in 0.1N HCl medium, a rate of dissolution (δ) of the magnesium contained therein of less than or equal to 60% by weight relative to the total weight of the Mg provided by the first magnesium source, and (b) a second magnesium source in a topical preparation. A method for treating skin for stress, fatigue or skin barrier deficiencies, as well as for stratum corneum hydration, includes orally and topically administering magnesium sources (a) and (b), respectively. | 04-28-2011 |
20110111027 | IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE - The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form. | 05-12-2011 |
20110159094 | EXTENDED RELEASE COMPOSITIONS FOR HIGH SOLUBILITY, HIGH PERMEABILITY ACTIVE PHARMACEUTICAL INGREDIENTS - A novel composition comprising a tablet, comprising a highly soluble active pharmaceutical ingredient, which is then coated with a coating. The core is preferably a tablet. The coating preferably comprises any type of suitable extended release polymer, with the proviso that the polymer does not comprise an enteric polymer. | 06-30-2011 |
20110159095 | TREATMENT OF ADRENAL INSUFFICIENCY - The disclosure relates to a pharmaceutical formulation, for example a tablet, adapted for delayed and sustained release of hydrocortisone and a treatment regime that uses said tablet in the treatment of adrenal insufficiency. | 06-30-2011 |
20110165239 | PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN - The present invention provides stable pharmaceutical compositions comprised of atorvastatin and sodium bicarbonate or L-arginine. The compositions are prepared as bulk drug compositions and also as oral dosage units, such as tablets or capsules. The compositions are useful for preparation of monolithic and bi-layer tablets containing atorvastatin as the only active agent or combined with one or more additional active agents. The compositions are useful for treating hypercholesterolemia and related conditions. | 07-07-2011 |
20110177167 | Hydrophilic/Lipophilic Polymeric Matrix Dosage Formulation - An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet. | 07-21-2011 |
20110177168 | COMPOSITION - A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties. | 07-21-2011 |
20110212175 | COMBINATION PREPARATION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKER AND HMG-COA REDUCTASE INHIBITOR - Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs. | 09-01-2011 |
20110262539 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 10-27-2011 |
20110305756 | COATED SOLID PREPARATION - A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure. | 12-15-2011 |
20110311627 | CONTROLLED RELEASE LEVETIRACETAM FORMULATIONS AND METHODS FOR PRODUCING THE SAME - Pharmaceutical compositions in the form of tablets are disclosed including water-soluble active ingredients such as levetiracetam and a polymer component which primarily includes water-insoluble polymers comprising between 60% and 100% of the polymer component in the tablet core, preferably the entire polymer component in the tablet core. The pharmaceutical compositions can also include an extended-release coating including both water-soluble and water-insoluble polymers. | 12-22-2011 |
20120003312 | Multilayer Minitablets with Different Release Rates - Multilayer minitablets for oral administration of a combination of active pharmaceutical ingredients which release the active pharmaceutical ingredient at different release rates are described. | 01-05-2012 |
20120034303 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX - A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s). | 02-09-2012 |
20120156294 | Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration - The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above. | 06-21-2012 |
20120164221 | COMBINATIONS OF HMG-COA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT - The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy, or rhabdomyolysis. | 06-28-2012 |
20120177736 | METHOD FOR TREATING A PATIENT IN NEED OF ASPIRIN THERAPY - The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer. | 07-12-2012 |
20120201887 | Pharmaceutical Formulation - A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%. | 08-09-2012 |
20120201888 | Pharmaceutical Compositions - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 08-09-2012 |
20120201889 | MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain. | 08-09-2012 |
20120258173 | Functionally-Coated Multilayer Tablets - Multilayer functionally coated tablets for oral administration of one or more active pharmaceutical ingredients containing one or more quick release layers and one or more modified release layers separated by an inert layer are provided. Also provided are methods for formulation and use of these tablets. | 10-11-2012 |
20120276201 | COMPOSITIONS AND METHOD FOR TREATMENT AND PROPHYLAXIS OF INFLAMMATORY BOWEL DISEASE - Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD. | 11-01-2012 |
20120282338 | Extended Release Formulation - The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof. | 11-08-2012 |
20130034605 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PALIPERIDONE - An extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients and process for preparing the same. The present invention particularly relates to an extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients wherein the core is coated with multiple coatings. | 02-07-2013 |
20130089609 | CONTROLLED RELEASE NUCLEATED TABLET - Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucleus contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and the outer layer contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and a gel-forming water-soluble polymer that is in an amount of 16 (w/w) % or more relative to the weight of the outer layer. | 04-11-2013 |
20130115289 | ANTI-FLUSH COMPOSITIONS - Disclosed are pharmaceutical compositions having a portion of aspirin for intraoral release and another aspirin for gastrointestinal release. The compositions can further include niacin. Methods of using such compositions to treat diseases or conditions suitably treated by niacin are also provided which result in reduced flushing. | 05-09-2013 |
20130142874 | PHARMACEUTICAL COMPOSITIONS BASED ON DICLOFENAC - New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher C | 06-06-2013 |
20130149379 | GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT - Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate. | 06-13-2013 |
20130183383 | PHARMACEUTICAL COMPOSITIONS FOR CALANOLIDES, THEIR DERIVATIVES AND ANALOGUES, AND PROCESS FOR PRODUCING THE SAME - The present invention relates to pharmaceutical compositions of calanolides, their derivatives and analogues, and process for producing the same having enhanced solubility and bioavailability for oral or parenteral administration. The invention further provides for a method of using the disclosed compositions for the treatment and prevention of retroviral diseases such as human immunodeficiency, specifically HTV-1 and mycobacterial diseases especially tuberculosis infections in mammals, particularly humans. | 07-18-2013 |
20130266650 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 10-10-2013 |
20130266651 | LONG ACTING DUAL RELEASE PRODUCT CONTAINING CARBINOXAMINE AND PSEUDOEPHEDRINE - Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants. | 10-10-2013 |
20130273158 | EXTENDED RELEASE COMPOSITIONS OF QUETIAPINE - Described herein are pharmaceutical compositions of quetiapine, more particularly extended release compositions of quetiapine or its pharmaceutically acceptable salts comprising carboxymethyl ethyl cellulose, a non-gelling, hydrophobic release controlling polymer, and processes for preparing the same. | 10-17-2013 |
20130273159 | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments - Multi-layer solid oral dosage immediate release and extended release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments. | 10-17-2013 |
20130295177 | CONTROLLED RELEASE HYDROCODONE - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 11-07-2013 |
20130302418 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 11-14-2013 |
20140010876 | PHARMACEUTICAL ADMINISTRATION FORMS COMPRISING 5-CHLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE - The present invention relates to solid orally administrable pharmaceutical administration forms comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (rivaroxaban, active compound (I)), wherein a partial amount of the active compound (I) is released rapidly and a partial amount is released in a controlled manner (modified, retarded, delayed), and to processes for their preparation, their use as medicaments and their use for the prophylaxis, secondary prophylaxis or treatment of disorders. | 01-09-2014 |
20140030328 | DUAL RELEASE ORAL TABLET COMPOSITIONS OF DEXLANSOPRAZOLE - Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders. | 01-30-2014 |
20140030329 | Methods for Treating Insomnia - Methods for treating insomnia in humans not suffering from any psychiatric disorders using quetiapine. | 01-30-2014 |
20140056979 | Controlled Release Pharmaceutical Dosage Forms - The present invention relates to pharmaceutical multilayer dosage forms, for example to a tamper resistant dosage form comprising a first layer comprising an active agent and a second layer not comprising said active agent, and processes of manufacture, uses, and methods of treatment thereof providing essentially zero order release. | 02-27-2014 |
20140065213 | Sustained Release Paracetamol Formulations - The present invention is directed to twice daily sustained release pharmaceutical composition of paracetamol having an immediate release phase of paracetamol and a sustained release phase of paracetamol, said composition having unique and advantageous pharmacokinetic properties and a pharmaceutical composition comprising only a sustained release phase of paracetamol having unique and advantageous pharmacokinetic properties. | 03-06-2014 |
20140127295 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES - The present disclosure describes a composition and a kit having a plurality of compounds for use in the treatment of inflammatory joint diseases and chronic inflammatory connective tissue diseases, such as Rheumatoid Arthritis (RA). The disclosure also relates to a process of obtaining the composition and the method of treating diseases by administration of the compositions. | 05-08-2014 |
20140127296 | Pharmaceutical preparation and method for treatment of diabetes - A pharmaceutical composition for use in oral medication for the treatment of diabetes mellitus can include an antacid agent with an enteric coating, which permits the antacid agent to be delivered in the small intestines where it reduces acidity thereby causing a lowering of blood sugar levels. The pharmaceutical composition can be packaged in various tablet forms, including standard tablets and multiple pellet tablets. The pharmaceutical composition can further include an enteric coated gastric acid secretion inhibitor. Also disclosed is a method for the treatment of diabetes mellitus. | 05-08-2014 |
20140134248 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 05-15-2014 |
20140178471 | MULTI-LAYERED RELEASE FORMULATION - The present invention in general relates to a pharmaceutical dosage form comprising a multi-layered release formulation formed by co-extrusion. Said formulation in particular comprises a core layer comprising at least one polymer selected from polycaprolactone, ethylcellulose, or combinations thereof; and a coat layer comprising at least one (co)polymer selected from the list comprising: polyethylene oxide; polyethylene glycol; Basic Butylated Methacrylate (co)polymer; a (co)polymer of polyvinylcaprolactam, PEG and polyvinylacetate; or combinations thereof. | 06-26-2014 |
20140186439 | STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine. | 07-03-2014 |
20140212490 | TABLET FOR PULSED DELIVERY - A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed. | 07-31-2014 |
20140255484 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF DEXLANSOPRAZOLE - Modified release oral pharmaceutical compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof in the form of a bilayer tablet and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders. | 09-11-2014 |
20140271850 | Controlled-Release Pharmaceutical Compositions Comprising Lamotrigine and Methods of Producing Same - Described herein is a pharmaceutical composition comprising lamotrigine as an active ingredient providing a prolonged release characteristic to allow once a day dosage regime. The composition comprises lamotrigine and a swelling agent forming a core or an extended-release composition. The core or an extended-release composition may be coated with a hydrophobic, pH-independent polymer to provide a modified extended-release composition. The formulation may comprise other pharmaceutically acceptable excipients that may act as additional release rate modifier(s), e.g., a pore forming agent in the hydrophobic polymer coat/film. Also described are the processes of preparing such dosage forms and their use. | 09-18-2014 |
20140271851 | ANTIEMETIC EXTENDED RELEASE SOLID DOSAGE FORMS - A pharmaceutical formulation includes (1) a first dosage component comprising: a core comprising a non-ionic polymer matrix, a first amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed within the matrix, and an electrolyte dispersed within the matrix; a first seal coat surrounding the core, the first seal coat comprising a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed therein; and (2) a second dosage component comprising: a core comprising a third amount of ondansetron or an equivalent amount of an ondansetron salt thereof, at least one filler, and a lubricant; and a coating surrounding the core, the coating comprising water and a mixture of methacrylic acid-alkyl acrylate copolymers with alkaline groups. | 09-18-2014 |
20140271852 | SUSTAINED RELEASE FORMULATION OF NALBUPHINE - Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. | 09-18-2014 |
20140271853 | NOVEL FORMULATIONS OF PROTON PUMP INHIBITORS AND METHODS OF USING THESE FORMULATIONS - The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease including nocturnal acid breakthrough, or the symptoms associated therewith | 09-18-2014 |
20140294956 | GASTRIC RETENTIVE EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS - The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state. | 10-02-2014 |
20140308349 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat a subject, including reducing or eliminating an adverse effect associated with the analgesics. | 10-16-2014 |
20140314848 | PHARMACEUTICAL COMPOSITIONS OF ANTIHYPERTENSIVES - The present invention describes antihypertensive pharmaceutical formulations particularly formulations of losartan and indapamide. | 10-23-2014 |
20140356428 | TAMPER RESISTANT DOSAGE FORM WITH BIMODAL RELEASE PROFILE - The invention relates to a pharmaceutical dosage form comprising
| 12-04-2014 |
20140363505 | NEW COMBINATION - The invention relates to a new fixed dose combination of benazepril with pimobendan. | 12-11-2014 |
20140370086 | SUBLINGUAL IMMUNOTHERAPY WITH REDUCED ORAL ITCHINESS - Sublingual immunotherapy (SLIT) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with SLIT, which can improve patient compliance. An antihistamine and/or a leukotriene inhibitor can also be added along with the mast cell stabilizer. Multi-layer and/or coated tablets, and flexible paired ampoules with special features to advantageously time the dose of the allergen relative to the dose of the mast cell stabilizer, have been provided to effectively administer the improved sublingual immunotherapy in a highly convenient manner. Methods, preparations, and apparatuses for administration of SLIT, apparatus for sequentially dispensing, methods for producing a sequence of allergen doses with reduced adverse reactions, methods for producing a stock solution for dilution, and methods for producing cooperative pre-filled vials are also disclosed. | 12-18-2014 |
20140377349 | CONTROLLED RELEASE ORAL DOSAGE FORM COMPRISING OXYCODONE - The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration of oxycodone once a day. | 12-25-2014 |
20140377350 | BILAYER TABLET FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN - Bilayer Tablet Formulations of Flurbiprofen And Glucosamin The present invention relates to a bilayer tablet formulation of flurbiprofen and glucosamine. Particularly, the present invention relates to a bilayer tablet formulation having a controlled release flurbiprofen and immediate release glucosamine; furthermore relates to their process and use. | 12-25-2014 |
20140377351 | METHOD AND COMPOSITION FOR ENHANCING COGNITION IN ALZHEIMER'S PATIENTS - The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist. | 12-25-2014 |
20140377352 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE MORPHINE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 12-25-2014 |
20150017242 | Bilayer Tablet of Dronedarone - The present invention relates to multi component composition of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of multi component composition of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day. | 01-15-2015 |
20150024048 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT - Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising | 01-22-2015 |
20150030677 | Tamper Resistant Immediate Release Formulations - Disclosed is an immediate release solid oral dosage form comprising (i) an active agent; and (ii) a material that is sensitive to acidic pH; | 01-29-2015 |
20150037410 | PHARMACEUTICAL COMPOSITIONS OF RANOLAZINE AND DRONEDARONE - The present disclosure relates to a solid composition comprising ranolazine and a spray-dried phosphoric acid salt of dronedarone in a bilayer tablet. | 02-05-2015 |
20150072006 | Pharmaceutical Formulations - The invention relates to drug preparations with controlled active ingredient released in the form of microtablets which contain, as active ingredient, flupirtin or one of its physiologically compatible salts, and to processes for their production. | 03-12-2015 |
20150125525 | DELAYED RELEASE DRUG FORMULATION - Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base. Advantages of formulations according to the present invention include accelerated release of the drug when exposed to colonic conditions and reduction or elimination of a food and/or alcohol effect on drug release after administration. | 05-07-2015 |
20150132380 | A DELAYED RELEASE DRUG FORMULATION - Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an outer layer and at least one layer between the core and the outer layer selected from the group consisting of an isolation layer and an inner layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base. The isolation layer comprises a non-ionic polymer which is soluble in intestinal fluid or gastrointestinal fluid. The outer is applied directly to the inner layer or the isolation layer using a coating preparation formed by combining the first polymeric material in an aqueous medium with a second polymeric material in an organic medium. Advantages of formulations according to the present invention include accelerated release of the drug when exposed to colonic conditions and reduction or elimination of a food and/or alcohol effect on drug release after administration. | 05-14-2015 |
20150140095 | ONCE-A-DAY OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 05-21-2015 |
20150297525 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 10-22-2015 |
20150306040 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 10-29-2015 |
20150320685 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 11-12-2015 |
20150328161 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 11-19-2015 |
20150328209 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 11-19-2015 |
20150328210 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 11-19-2015 |
20150328211 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 11-19-2015 |
20150328212 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 11-19-2015 |
20150328213 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 11-19-2015 |
20150328246 | ORALLY ADMINISTRATABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT - Drug tablets that include a controlled release layer of a moisture-sensitive active agent are prepared with a lipidic matrix forming excipient, a water-soluble, channel forming excipient and a filler, each being non-hygroscipic. The tablets are formed in a process where the components are blended in the absence of moisture and in particulate form. | 11-19-2015 |
20150342877 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM - An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track. | 12-03-2015 |
20150342968 | STABLE PHARMACEUTICAL COMPOSITION FOR TREATING OSTEOPOROSIS - This invention provides pharmaceutical compositions which increase the bioavailability of risedronate sodium and provides vitamin D3 with greater stability; these compositions are useful in the inhibition of bone resorption. | 12-03-2015 |
20150352129 | ASPIRIN FORMULATION FOR INCREASED EFFICACY - Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition. | 12-10-2015 |
20150352189 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS - In one embodiment, the invention provides a method of regenerating organs and tissues in a subject suffering from one or more organ or tissue manifestations of glucose supply side associated metabolic syndrome, the method comprising: (a) confirming that the subject suffers from or is at risk for suffering from organ and/or tissue damage associated with a glucose supply side associated metabolic syndrome; and (b) co-administering to the subject an effective amount of a pharmaceutical composition comprising a first and optionally a second active composition, said first active composition comprising an ileal brake hormone releasing substance encapsulated within an enteric coating which releases said substance within said subject's ileum and ascending colon causing release of at least one ileal brake hormone from L-cells of said subject, said optional second active composition being formulated in immediate and/or early release form in an over coating onto said enteric coating, wherein said second composition is beneficial to at least one aspect of said subject's metabolic syndrome manifestations. Coadministration methods with a second pharmaceutical composition are also disclosed. | 12-10-2015 |
20150374650 | PHARMACEUTICAL COMPOSITIONS CONTAINING DEXKETOPROFEN AND TRAMADOL - A pharmaceutical composition as a solid oral dosage form is described, comprising:
| 12-31-2015 |
20150374651 | EXTENDED, DELAYED AND IMMEDIATE RELEASE FORMULATION METHOD OF MANUFACTURING AND USE THEREOF - Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents. | 12-31-2015 |
20150374653 | GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERS - The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction. | 12-31-2015 |
20150374688 | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof. - The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a multilayered coated pharmaceutical composition comprising at least two compartments of metformin or salts thereof exhibiting immediate and extended release and at least one compartment of sitagliptin and metformin or salts thereof exhibiting immediate release. The invention also includes process of preparing such compositions and method of use of such compositions for treating type II diabetes. | 12-31-2015 |
20160000715 | Combinations of Oral Medicaments Bonded by a Wrapping - An oral pharmaceutical dosage form is provided which contains at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another. At least one of the medicaments can be chosen from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, and clopidogrel. | 01-07-2016 |
20160008312 | BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES | 01-14-2016 |
20160008375 | PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM | 01-14-2016 |
20160030352 | DUAL DRUG DOSAGE FORMS WITH IMPROVED SEPARATION OF DRUGS - Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion. | 02-04-2016 |
20160030419 | ONCE-A-DAY OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 02-04-2016 |
20160051474 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 02-25-2016 |
20160074329 | RATE MODULATED DELIVERY OF DRUGS FROM A COMPOSITE DELIVERY SYSTEM - This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorpion location of the human or animal body, preferably the gastrointestinal tract, in predetermined rate-modulated manner. The dosage form is orally ingestible and is in the form of a multi-layered tablet or capsule containing a multiplicity of multi-layered granules. Each layer contains one or more APIs mixed or blended with at least one and preferably a matrix of polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in that desired absorption location. | 03-17-2016 |
20160095828 | Compositions and Methods for Treating Metabolic Disorders - Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine. | 04-07-2016 |
20160106678 | METHOD FOR DELIVERING A PHARMACEUTICAL COMPOSITION TO PATIENT IN NEED THEREOF - The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof. | 04-21-2016 |
20160375013 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of an analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 12-29-2016 |
20160375014 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of an analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 12-29-2016 |
20160375015 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 12-29-2016 |
20160375017 | Solid Pharmaceutical Compositions for Treating HCV - The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion. | 12-29-2016 |
20170231943 | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE FOR ADMINISTRATION AT A LOW DAILY DOSE | 08-17-2017 |
20190142755 | TABLET-IN-TABLET PHARMACEUTICAL COMPOSITION COMPRISING CYCLOPHOSPHAMIDE AND CAPECITABINE | 05-16-2019 |
20220133720 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA - A pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia is provided. Compartments containing a drug are formulated in separate forms to solve problems related to the dissolution and absorption of the drug due to drug interaction, and a biologically equivalent preparation can be obtained compared with a conventional single preparation. | 05-05-2022 |